MK-2048

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
MK-2048.svg
MK-2048
Systematic (IUPAC) name
(6S)-2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-9-hydroxy-N,6-dimethyl-1,10-dioxo-6,7-dihydropyrazino[3,4]pyrrolo[3,4-b]pyridazine-4-carboxamide
Clinical data
Legal status
  • Investigational New Drug
Identifiers
ATC code none
PubChem CID: 11554427
ChemSpider 25058456
ChEMBL CHEMBL1237018
Chemical data
Formula C21H21ClFN5O4
Molecular mass 461.87 g/mol
  • CCN1CC(N2C3=C(C(=O)C2=C1O)C(=O)N(N=C3C(=O)NC)CC4=CC(=C(C=C4)F)Cl)C
  • InChI=1S/C21H21ClFN5O4/c1-4-26-8-10(2)28-16-14(18(29)17(28)21(26)32)20(31)27(25-15(16)19(30)24-3)9-11-5-6-13(23)12(22)7-11/h5-7,10,32H,4,8-9H2,1-3H3,(H,24,30)/t10-/m0/s1
  • Key:IOYLKNABOQYKKY-JTQLQIEISA-N

MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP).[1]

It is being developed by Merck & Co.[2]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
  1. ↑ Keith Alcorn. Ralvetgravir shows potential for use as PrEP drug AIDSmap.com. 28 April 2009. Accessed 8 Nov 2009.
  2. ↑ Mark Mascolini. Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15–17, 2009, Amsterdam. Accessed 8 Nov 2009.
Retrieved from "https://infogalactic.com/w/index.php?title=MK-2048&oldid=2482509"